Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amyloid-beta precursor protein messenger RNA (APP mRNA)
- Target
- APP mRNA
- Molecular classification
- Other (mRNA; protein-coding transcript)
01
Overview
APP mRNA is the messenger RNA transcript encoded by the APP gene, responsible for the synthesis of amyloid-beta precursor protein. APP mRNA is best known for its role in the molecular pathology of Alzheimer's disease, as alternative splicing and expression levels of different APP mRNA isoforms are linked to amyloid plaque formation and neurodegeneration. Modulation of APP mRNA using RNA interference or antisense oligonucleotides is an investigational therapeutic strategy aiming to reduce amyloid-beta production for diseases such as Alzheimer's. APP mRNA also serves as a molecular biomarker for diagnostic and research purposes in neurodegenerative and some cancer settings.
- Other names
- APP transcriptAmyloid precursor protein mRNAAmyloid beta precursor protein mRNA
02
Mechanism of action
Inhibition of APP mRNA via RNAi or antisense leads to reduced production of amyloid-beta precursor protein and subsequent decrease in amyloid-beta peptides
03
Biological functions
Encodes for amyloid-beta precursor protein synthesisRegulates translation of APP protein isoformsBiomarker or molecular readout for APP expression, particularly in neurodegenerative research
04
Disease associations
Neurodegenerative disease (Alzheimer's disease, cerebral amyloid angiopathy)Cancer (as a biomarker and putative regulatory target in cancer biology)
05
Safety considerations
Potential for off-target gene silencing or immune responses in RNA-targeted therapeuticsDisruption of normal APP function, which is implicated in neural development, synaptic function, and cell adhesion/viability
06
Interacting drugs
RNA interference (RNAi) agents and antisense oligonucleotides targeting APP gene transcripts
07
Biomarkers
APP mRNA isoform ratios (e.g., APP-751/APP-695 mRNA ratio) for Alzheimer's disease plaque burden assessmentAPP mRNA expression levels as a diagnostic or disease progression marker
Beyond the preview
Go deeper on Amyloid-beta precursor protein messenger RNA (APP mRNA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amyloid-beta precursor protein messenger RNA (APP mRNA).